Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival.

Borbath, Ivan; Lhommel, Renaud; Guiot, Yves; Coche, Emmanuel; Sempoux, Christine

Borbath, Ivan; Lhommel, Renaud; Guiot, Yves; Coche, Emmanuel; Sempoux, Christine.

Affiliation

Borbath I; Cliniques Universitaires St. Luc Brussels, Belgium. ivan.borbath@uclouvain.be

Acta Gastroenterol Belg ; 75(2): 270-3, 2012 Jun.

Article in En | MEDLINE | ID: mdl-22870795

Subject(s)

Antineoplastic Agents/therapeutic use; Carcinoma, Hepatocellular/drug therapy; Liver Neoplasms/pathology; Lung Neoplasms/drug therapy; Lymph Nodes/pathology; Peptides, Cyclic/therapeutic use; Somatostatin/analogs & derivatives; Carcinoma, Hepatocellular/secondary; Carcinoma, Hepatocellular/surgery; Disease-Free Survival; Female; Humans; Liver Neoplasms/surgery; Lung Neoplasms/secondary; Lymphatic Metastasis; Mediastinum; Middle Aged; Remission Induction; Somatostatin/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Peptides, Cyclic / Somatostatin / Carcinoma, Hepatocellular / Liver Neoplasms / Lung Neoplasms / Lymph Nodes / Antineoplastic Agents Type of study: Clinical_trials Limits: Female / Humans / Middle aged Language: En Journal: Acta Gastroenterol Belg Year: 2012 Document type: Article Affiliation country: Belgium Country of publication: Belgium

Search on Google

Add to My VHL

XML

PubMed Links